KPTI נכסי החברה Karyopharm Therapeutics

Karyopharm Therapeutics (KPTI) specializes in developing drugs to combat myeloma, for which demand remains independent of market fluctuations and seasonality. This chart of total assets on GURU.Markets, which reaches 108.10, confirms its status as a defensive asset during recessionary periods. Management is successfully bringing innovations to market, consistently expanding the list of medical indications and reducing operating expenses.

Assessing the margin of safety for Karyopharm Therapeutics (KPTI) requires an analysis of the actual asset scale, which this indicator calculates inversely via daily ROA to eliminate market noise and price volatility. The trend in total asset value allows for the verification of the business's intrinsic value, which is critical when diversifying the application of oncology drugs in the therapy of various types of cancer to mitigate patent risks.